A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy

Haroon, Muhammad; O’Gradaigh, Donncha; Foley-Nolan, D.

doi:10.1093/rheumatology/kem003

Cited by 16 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two case reports recently published focused on rituximab treatment for Raynaud phenomenon during MCTD are contradictory, one reported an efficiency of rituximab12 which was not confirmed in the second 13. Thus, rituximab should be evaluated as an alternative treatment of MCTD.…”

Section: Discussionmentioning

confidence: 96%

Good outcome after rituximab treatment for a mixed warm and cold autoimmune haemolytic anaemia

Granel

Rossi²,

Bernard³

et al. 2009

Case Reports

View full text Add to dashboard Cite

Mixed warm and cold autoimmune anaemia is a rare haemolytic anaemia that is commonly associated with lymphoproliferative disorders and autoimmune diseases. Although steroid therapy is the first-line treatment, rituximab represents a good alternative. The present study reports on a successful treatment with rituximab in a young woman suffering from a mixed warm and cold autoimmune haemolytic anaemia associated with a mixed connective tissue disease.

show abstract

Section: Discussionmentioning

confidence: 96%

Good outcome after rituximab treatment for a mixed warm and cold autoimmune haemolytic anaemia

Granel

Rossi²,

Bernard³

et al. 2009

Case Reports

View full text Add to dashboard Cite

show abstract

“…Regarding MCTD, a successful treatment with RTX (in combination with CCS, CYC, and iloprost) has been reported in a case of severe, refractory RP [10], while on the contrary, Dunkley et al reported a case of MCTD with scleroderma spectrum in which RTX was not able to control RP [11]. Moreover two MCTD cases in which TPE was able to treat visceral RP with multiple organ damage (treated with combination with CYA and CCS) [12] and acute renal failure (in combination with CYC and captopril) [13] have been described.…”

Section: Discussionmentioning

confidence: 99%

A Case of Subacute Cutaneous Lupus Erythematosus in a Patient with Mixed Connective Tissue Disease: Successful Treatment with Plasmapheresis and Rituximab

Fantò

Salemi

Socciarelli

et al. 2013

Case Reports in Rheumatology

View full text Add to dashboard Cite

A 30-year-old woman affected by Mixed Connective Tissue Disease with scleroderma spectrum developed a facial eruption, a clinical and histological characteristic of subacute cutaneous lupus erythematosus (SCLE). Speckled anti-nuclear antibodies, high-titer anti-ribonucleoprotein1, anti-Sm, anti-Cardiolipin (aCL) IgG/IgM, and anti-Ro/SSA antibodies were positive. SCLE was resistant to Azathioprine, Hydroxychloroquine, and Methotrexate while Mycophenolate Mofetil was suspended due to side effects. Subsequently, the patient was treated with three cycles of therapeutic plasma exchange (TPE) followed, one month after the last TPE, by the anti-CD20 antibody Rituximab (RTX) (375 mg/m2 weekly for 4 weeks). Eight and 16 months later the patient received other two TPE and RTX cycles, respectively. This therapeutic approach has allowed to obtain a complete skin healing persistent even after 8-month follow-up. Moreover, mitigation of Raynaud's phenomenon, resolution of alopecia, and a decline of aCL IgG/IgM and anti-Ro/SSA antibodies were observed.

show abstract

“…These negative effects could be lowered by adding steroid sparing agents. On the analogy of recently published case reports of patients with idiopathic retroperitoneal fibrosis, who have been treated with mycophenolate mofetil, good results could have been expected for idiopathic mediastinal fibrosis [12,13,14]. Mycophenolate mofetil is an inhibitor of guanosine nucleotide synthesis and consequently inhibits the proliferation of T and B lymphocytes.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Mediastinal Fibrosis with Mycophenolate Mofetil

Witschi¹,

Gugger²,

Nicod³

2009

Respiration

View full text Add to dashboard Cite

We present the case of a 67-year-old male patient with mediastinal and retroperitoneal fibrosis. In Europe, this is a rare disease. Treatment was established to prevent complications due to strictures or compressions. Because of his diabetes, a therapy of low-dose prednisone combined with mycophenolate mofetil, known as steroid sparing agent, was applied. As a result, the radiological follow-up showed a marked decrease in the mediastinal and retroperitoneal masses.

show abstract

A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy

Cited by 16 publications

References 7 publications

Good outcome after rituximab treatment for a mixed warm and cold autoimmune haemolytic anaemia

Good outcome after rituximab treatment for a mixed warm and cold autoimmune haemolytic anaemia

A Case of Subacute Cutaneous Lupus Erythematosus in a Patient with Mixed Connective Tissue Disease: Successful Treatment with Plasmapheresis and Rituximab

Treatment of Mediastinal Fibrosis with Mycophenolate Mofetil

Contact Info

Product

Resources

About